Combining TKIs with CD27/CD70 blockade can effectively eliminate human CD34+ CML stem/progenitor cells in xenografts and LSCs in a murine CML model, suggesting that CD70/CD27 interactions could be targeted to overcome treatment resistance in CML LSCs [89]. This evidence concerns the gene CD27 and chronic myelogenous leukemia, BCR-ABL1 positive.